Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Single Ascending Dose Study of RO7126209 in Healthy Japanese Subjects
jRCT2031210091Phase 1Completed
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- Jul 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label trial of trontinemab in Alzheimer's disease (AD) (4 arms), sponsored by Chugai Pharmaceutical Co., Ltd. Primary endpoint: Safety observations. Started Jul 2021; status: completed.
02
Drugs
trontinemab
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on jRCT2031210091.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031210091.